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Surllnlary 
Low recovery and poor retroviral vector infection efficiency  of hematopoietic stem cells has hindered 
application of gene therapy for diseases affecting blood-forming tissues. Developmental restriction 
(or death) of stem cells during ex vivo infection has contributed to these difficulties. In these 
studies we report that the cytokine leukemia inhibitory factor (LIF) directly or indirectly supported 
the survival of hematopoietic stem cells during culture of bone marrow with vector-producing 
fibroblasts, resulting in efficient recovery of stem cells able to compete for engraftment in irradiated 
recipient animals. The infection efficiency of hematopoietic stem cells recovered from these cultures 
was ~80%;  and all recipients (20/20) of the LIF-treated marrow were stably engrafted with 
the progeny of provirus-bearing stem cells. Expression of vector-encoded human adenosine deaminase 
(hADA) was detected in all recipients at levels averaging  15-50% of endogenous murine ADA 
in all their hematolymphoid tissues. Survival of stem cells in untreated cultures was ",'10% of 
that observed from LIF-treated cultures, resulting in poor engraftment of recipient animals with 
transplanted cells. The infection efficiency of the few stem cells recovered from untreated cultures, 
however, was high ("080%), suggesting that LIF did not have an effect on infection efficiency 
per se, but acted at the level of stem cell survival. Consistent with the poor engraftment observed 
in the control animals, expression of vector-encoded ADA was only ~4-20% of the endogenous 
levels. These results support the postulated role of LIF as a regulator of hematopoiesis and suggest 
that  cytokine  stimulation can  positively affect  inefficient  retroviral  vector  transduction  in 
hematopoietic stem cells. 
A 
major limiting factor in the development of retroviral 
vector-mediated gene transfer for treatment of diseases 
affecting the blood and blood-forming tissues has been the 
low infection efficiency of hematopoietic stem cells in vitro 
(1-6).  Without positive selection, ~70%, or less, ofmurine 
transplant recipients can be shown to harbor proviral sequences 
in the differentiated progeny of donor stem cells. In these 
experiments, when an estimate was made, only ",,10%  of 
active stem cells were transduced (1, 2, 5). Although a 100% 
stem cell infection efficiency is not required to proceed from 
murine models to large animal or clinical models of gene 
therapy,  the infection efficiency must be high enough such 
that all transplanted recipients exhibit hematopoietic repopu- 
lation with the differentiated progeny of at least one infected 
stem cell. While positive selection in vitro has been used suc- 
cessfully to enrich for infected cells in murine transplanta- 
tion models (7, 8) it is not clear that this will be useful for 
human gene therapy. The large number of cells required for 
successful hematopoietic engraftment (ml0  s cells/kg body 
weight, reference 9) could preclude selection techniques as 
a substitute for efficient stem cell infection. 
It  has  been  suggested that  the low observed infection 
efficiency is a result of stem cell quiescence during cocultiva- 
tion of bone marrow with vector-producing cell lines. In- 
tegration of proviral intermediates is sensitive to target cell 
DNA replication (10) and hematopoietic stem cells are pre- 
dominantly quiescent, spending >97% of the cell cycle transit 
time in the Go or G1 phase (11). It has recently been shown 
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preintegration proviral intermediates for at least 5 d (12). The 
efficiency of integration during subsequent replication declined 
as a function of time postinfection. An alternative explana- 
tion for low stem cell infection efficiency is that replicating, 
and therefore efficiently infected, stem cells  are committed 
to differentiate during  culture before transplantation. 
A prediction of either of these models is that the provision 
of appropriate cytokines to bone marrow culture should en- 
hance vector-mediated gene transfer to stem cells by stimulating 
self-replication,  or by otherwise maintaining  the stem cell 
proliferative and differentiative capacity. I1,3 and II.6 have 
been reported to be useful for prolonging  survival of stem 
cells in vitro, but the infection efficiency was not significantly 
improved  (13);  and  only  m40%  of the  recipient  animals 
were shown to harbor provirus-containing  cells 4 mo post- 
transplantation. 
We have been studying other recombinant cytokines, in- 
cluding the leukemia inhibitory factor (LIF) 1 to determine 
whether they might improve stem cell survival and retroviral 
vector infection  in vitro.  LIF preserves the developmental 
totipotency of embryonic stem (ES) cells in vitro (14,  15), 
and has allowed improved recovery and retroviral vector in- 
fection of spleen colony forming cells (CFU-S) and their pro- 
genitors (preCFU-S) after cocultivation with vector-producing 
fibroblasts (16).  In the present  study, we have investigated 
the effect of LIF on survival of, and gene transfer efficiency 
into, pluripotent hematopoietic stem cells in shortterm liquid 
bone marrow culture. We have developed a transgenic com- 
petitive repopulation assay that has allowed assay of cytokine 
effects on stem cell survival in vitro, and improved analysis 
of stem cell infection  efficiency. 
The results demonstrate that LIF directly or indirectly main- 
tained the stem cell repopulation capacity during shortterm 
coculture of bone marrow with retroviral vector-producing 
fibroblasts, and that most of the stem cells recovered from 
these cultures were productively-infected with the vector. Im- 
proved recovery of infected stem cells allowed nearly com- 
plete hematopoietic reconstitution with provirus-bearing cells 
in all recipients, and led to efficient and long-term expression 
of vector-encoded human  adenosine deaminase (hADA). 
Materials  and Methods 
Cell Lines.  Construction  of the retroviral vector AN2ADA has 
been described (1). Development of the cell line (X1) producing 
this vector from the retroviral packaging cell line GP+E-86 (17) 
has also been described (2). The titer of the retrovirus was "~106 
infectious U/ml was determined by immunostaining  titration  and 
was free of replication-competent  virus. 
Transgenic  Mice.  Transgenic mice  were  generated  by DNA 
microinjection into one-ceU  stage FVB/N embryos, using standard 
techniques (18). The microinjected DNA was a 5.3-kb EcotkI-PstI 
fragment from the previously described genomic clone, gr19 (19). 
1 Abbreviations used in this paper: BM, bone marrow; dl, downless; ES, 
embryonic stem; hADA, human adenosine deaminase; LIF, leukemia 
inhibitory factor; SOD, specific optical density. 
The fragment consisted of a truncated SV40 large T antigen tran- 
scribed from an c~A-crystallin promoter (18, 19), integrated  into 
a different genomic locus in each family (Fig. 1). Expression of 
the transgene was limited to the lens of the eye, causing cataract 
or microphthalmia,  allowing identification of transgenic animals 
by visual inspection (20). Each family of mice, designated "/~' and 
"B", was bred to homozygosity (with respect to the transgene) 
by successive  brother-sister  matings. The control,  or A type, cells 
each harbored  approximately 20 copies of the transgene relative 
to a single-copy endogenous gene. The cytokine-treated, or B-type, 
cells each contained two copies of the integrated transgene. A high 
copy number family was selected for the control cultures because 
it was suspected that there would be a reduction  of stem cell ac- 
tivity in these cultures. Starting with 20 copies increased the sensi- 
tivity of detection by Southern blotting and thereby enhanced our 
ability to detect any residual stem cell activity from this population 
of cells. 
Infection  Protocol.  Bone marrow (BM) was collected from 10- 
to 12-wk-old female transgenic mice. BM, flushed from the femur 
and tibia of each hind leg, was cocultured (1:1 ratio) on monolayers 
of irradiated (20 Gy total dose) fibroblasts, as described (16). B-type 
donor marrow cells were  cultured  on irradiated  monolayers of 
GP+E-86  packaging  cells producing  the  replication-defective 
retrovirus AN2ADA with 0, 10, or 1,000 U/ml recombinant LIF 
derived from transfected COS cells (16). The LIF preparation had 
an activity of 75,000 U/ml as measured on DA-1 cells. A-type donor 
marrow  cells were cultured  on monolayer of GP+ E-86 without 
added cytokine. 
After 72 h cocultivation, BM cells were harvested by collecting 
non-adherent and loosely-attached  cells. Viable cell counts were per- 
formed by trypan  blue exclusion, followed by mixing  (1:1, A:B 
cells) and transplantation  into lethally-irradiated  syngeneic FVB 
recipients (8  x  106 cells/animal). 
Transplantation Protocol.  10-12-wk-old syngeneic (FVB) female 
recipients were irradiated  (10Gy) at least 4 h before transplant. 
Irradiation was performed with a '37Cs source (Gammacell 1000; 
Atomic Energy Ltd., Kanata, Ontario,  Canada) at a dose rate of 
2.5 Gy/min.  Recipients were injected intravenously with 8  x  106 
viable bone  marrow  cells in  culture  medium.  Transplantation 
recipients were housed in microisolator units placed on laminar- 
flow cage racks (Lab Products, Maywood, NJ); and fed sterilized 
rodent  chow and sterile, acidified water. 
Analysis of Hematopoietic  Tissues from Primary Recipients.  6 mo 
post-transplant  the  spleen, thymus,  bone marrow,  blood,  and 
thioglycolate (TG)-induced peritoneal exudate were harvested from 
each primary recipient. Splenic B cells were prepared by positive 
immunoselection with anti-mouse IgG-coated magnetic beads (Ad- 
vanced Magnetics Inc., Cambridge, MA), as per the manufacturer's 
recommendations.  The peritoneal exudate from each animal was 
cultured in vitro in the presence of IL,3 (10% WEHI3 conditioned 
medium)  to  enrich  for  adherent  macrophage/mast  cells. Bone 
marrow (5  x  10  4 cells) from each primary  recipient animal was 
injected into each of three irradiated (10 Gy) secondary recipients 
for isolation ofdonal stem cell progeny (repopulated spleen colony- 
forming cells, CFU-S).  Serum from three animals in each group 
was tested for the presence of replication-competent virus by marker 
rescue assay. ALl these samples were negative for helper virus activity. 
Protein extracts were prepared from each tissue and used to ana- 
lyze expression of vector-encoded hADA by Western blotting, as 
described (2). Quantitative  analysis of hADA expression was per- 
formed by video densitometry  of hADA bands on Western blots, 
followed by comparison to standard curves developed with purified 
hADA. These were generated by plotting the specific optical den- 
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human ADA (kindly provided by Dr. Rod Kellems, Baylor  Col- 
lege of Medicine) applied to each lane. SOD was calculated  by sub- 
tracting the integrated density of the individual lane background 
from integrated density of the hADA-specific band. The specific 
activity of the purified recombinant hADA was 2.0 x  10  s U-nM/ 
mR/rain at 25~  as determined by the spectrophotometric method 
(21). The standard curves were linear with respect to hADA quan- 
tity vs. SOD in the signal range of our samples (between 3.0 ng 
and 24 ng; r  =  0.9998). To quantitate the human ADA enzyme 
in the transplant recipient tissue specimens each immunoblot was 
then scanned. The amount of hADA was estimated in MOLT4 
(human T cell lymphoma cell line) controls and in experimental 
samples by interpolation based on this linear standard. A fixed 
amount of protein extract from MOLT4 was run on each immu- 
noblot  gel (7.2 #g;  specific activity 425  U-nM/mg/min corre- 
sponding to 16.2 ng or 3.25 U hADA). This standard was used 
to normalize the values from each experimental sample by refer- 
ence to the efficiency  of  detection on each blot: detection efficiency 
(DE)  =  estimated MOLT4 U hADA/3.25  U (1). The quantity 
of hADA in the experimental samples was calculated by the fol- 
lowing equation: U hADA activity  =  (est. sample ng hADA) 
(specific activity rhADA)/(#g  protein) (DE) (2). 
High molecular  weight DNA was prepared from each sample, 
except blood, and subjected to analysis  of transgene representation 
and proviral integration by Southern blotting and PCR. Quantita- 
tive video densitometry of transgene band intensities on Southern 
blots, compared to known copy number controls, allowed estima- 
tion of  competitive ability and extent of repopulation by each type 
of marrow; while assay  of proviral integration allowed estimation 
of vector infection and expression efficiencies. 
For transgene analysis,  genomic DNA (5 #g) was digested with 
a restriction endonuclease that cuts only once in the transgene 
(BamHI),  releasing unique-length  DNA  fragments from  each 
marrow type (Fig. 1). Digested  DNAs were electrophoresed  in 0.8% 
agarose for 48 h, at room temperature  and 30 voks. Gels  were  blotted 
onto paired (one for the upper half of the gel, fragments greater 
than 2K bp; and one for the lower half, less than 2K bp) nylon 
membranes (GeneScreen Plus; NEN Research Products, Boston, 
MA) as per the manufacturer's  recommendations.  A 650-bp HindlII- 
HindlII fragment of the plasmid pGr4 (19), containing parts of 
the transgene and mouse endogenous downless (dl) locus, was la- 
beled with c~-3~p-dCTP by random hexamer priming. The probe 
hybridized to both the transgenic bands and the endogenous dl 
locus, providing a convenient single-copy control. Hybridization 
in 5x SSPE, 1% SDS (65~  overnight) to the membrane blotted 
with >2K bp fragments, followed by washing at high sC'ingency 
(0.1x  SSC, 1% SDS, 65~  and autoradiography (XAR-5 film, 
Eastman-Kodak, Rochester, NY and Lightning Plus intensifying 
screen) at -70~  allowed detection of transgenic bands. Quanti- 
tation of  Southern blots by video densitometry allowed  estimation 
of repopulation by each marrow type in each tissue. SOD was mea- 
sured and calculated as described above for the immunoblot anal- 
ysis. Normalization for DNA loads and hybridization efficiency  for 
each lane was accomplished  by the presence of the internal, single- 
copy control in each lane (endogenous dl locus). DNAs from each 
parental strain (A and B) were also included on all gels to provide 
a transgene  copy number control. The adjusted  SOD of  each sample 
band was compared to the adjusted SOD of the control transgene 
bands to achieve an estimate of hematopoietic repopulation by each 
donor marrow. Adjusted  band intensity = (SOD sample) x (SOD 
dl sample)/(SOD dl control) (3); and percent reconstitution = (ad- 
justed band intensity/control transgene intensity)  x  100 (4). 
For analysis  of proviral integration, the half of each membrane 
pair  that  contained <2K bp  DNA  fragments  was  hybridized 
(5x  SSPE, 1% SDS, 65~  overnight) with a 32P-labeled hADA 
cDNA probe. Washing at 0.5x SSC at 55~  followed  by autora- 
diograpby allowed detection of a common 1.2K bp provirus band 
from all integration sites. Video densitometry of the provirus band 
in each lane compared to a known-copy-number  control DNA pre- 
pared from the AN2ADA packaging cell line, present on each gel, 
allowed quantitation  of proviral copy number for each tissue. 
Assay of CFU-S Derived  from Primary Recipients.  Analysis  of 
repopuhted CFU-S derived  from the bone marrow of  reconstituted 
primary recipients allowed estimation of the percent reconstitu- 
tion and clonality of transgenically-marked  stern cells. By deter- 
mining the percentage of CFU-S from individual  animals  containing 
each transgenic marker, an independent estimation of stem call 
repopulation was derived. A primary assumption with this method 
was that all CFU-S derived from each primary marrow were the 
progeny of transplanted or endogenously repopulating stem cells. 
The CFU-S assay was performed as described (16), and analysis 
of transgene representation and proviral integration was performed 
as described above. 
Results 
Transgenic Competitive Repopulation Assay.  To investigate 
the effect of LIF on stem cell survival in vitro, we designed 
a transgenic repopulation assay that compared the ability of 
LIF-treated bone marrow cells to compete with untreated 
cells  during reconstitution of hematopoiesis in  irradiated 
recipients (Fig.  1 A). To allow identification of the two sets 
of marrow, and to distinguish between endogenous repopu- 
lation and reconstitution with transplanted cells, we used two 
different families of inbred transgenic FVB mice as marrow 
donors (Fig.  1 B). A-type (control) bone marrow ceils were 
cultured in the absence of added growth factor on GP+ E-86 
retroviral packaging cells that were not transfected with a 
vector construct. B-type bone marrow cells were cultured 
on AN2ADA vector-producing  fibroblasts (GP+E-86 derived) 
to uniquely mark individual self-replicating stem cells. Recom- 
binant murine LIF was included in cultures of B-type cells 
at either 0,  10, or 1,000  U/ml. 
To prove equivalent reconstitution potential of each trans- 
genic marrow, ten recipients were transplanted with equal 
mixtures of  fresh marrow explants. Southern analysis of trans- 
gene representation in hematopoietic tissues six months post 
transplant demonstrated that neither marrow had a gross com- 
petitive advantage, leading to equivalent reconstitution with 
each transgenic marrow type in all tissues  (spleen,  thymus, 
bone marrow) and enriched cell populations (splenic B cell, 
macrophage) studied (Fig.  2, A  and B).  Southern analysis 
of transgene representation  in clonal stem cell progeny (spleen 
colony-forming  cells, CFU-S) derived from the bone marrow 
of reconstituted primary animals revealed that approximately 
20% of repopulation was by endogenous stem cells in these 
controls (Fig.  4 B). 
Effect of LIF on Stem Cell Survival In Vitra  To document 
the extent of stem cell loss during culture in the absence of 
added LIE we transplanted irradiated recipient animals with 
cells recovered from control cultures without added cytokines. 
839  Fletcher  et al. Figure 1.  Competitive repopulation assay. (A) Inbred (FVB) transgenic 
donors are used as a source of genetically-marked  bone marrow. Briefly, 
A-lineage cells were plated onto control cultures of irradiated packaging 
cells that did not produce the AN2ADA vector. B-type cells were plated 
onto AN2ADA-producing  fibroblasts. No growth factor was added to the 
"A" cultures, but 0-1,000 U/mL recombinant LIF was added to "B" cul- 
tures. After 72 h of cocultivation, nonadherent and loosely-adherent  cells 
were recovered from the two cultures, counted, and mixed at a 1:1 ratio. 
Irradiated (10 Gy) syngeneic  recipient animals were injected intravenously 
with 8  x  106 viable cells and allowed to recover without  experimental 
manipulation for 6 mo. At sacrifice,  primary hematopoietic tissues (spleen, 
thymus, bone marrow, blood) and enriched cell fractions (splenic B cells, 
peritoneal macrophages,  CFU-S)  were analyzed  as described  in the Materials 
and Methods; (B) Families of donor mice harbor multiple copies of the 
transgene, consisting of a truncated SV40 large T antigen driven by an 
c~-crystaUin promoter. A-type mice harbor a twenty copy transgene array 
visualized as a complex  multiple-band pattern on Southern  blot of  BamHI- 
digested DNA, while the B-type mice harbor a two copy array visualized 
as nonsegregating single-copy  bands on Southern blot of  BamHI-digested 
DNA. Only the lower band was used for quantitation of B-type cells on 
Southern blots because the upper band was often lost in the background 
of sheared DNA at the top of each lane. The presence of sequence from 
the endogenous routine downless (d/) locus on the plasmid fragment used 
as a probe for the transgene Southerns allows detection of the single-copy 
dl band as an internal control for DNA load in each lane. 
Culture of either transgenically marked bone marrow in the 
absence of LIF resulted in loss of the stem cell repopulating 
activity, as demonstrated by quantitative  reduction in copy 
number of the transgenic markers on Southern blots of DNA 
from hematopoietic  tissues harvested six months posttran- 
splant. Differentiated progeny of transgenically-marked stem 
cells accounted for ",~30%, on average, of total hematopoietic 
cells at sacrifice (Fig.  3 B).  Analysis of repopulated  CFU-S 
from these animals confirmed loss of the stem cells during 
culture (Fig. 4 B), with an average of 37%  of total CFU-S 
arising from transgenic donor cells.  ILepopulation by endog- 
enous stem cells  accounted for the balance of CFU-S and, 
therefore, differentiated progeny of hematopoietic stem cells 
in  these  control  animals. 
Figure 2.  Control animals transplanted with fresh marrow explants. 
(A) Southern analysis of transgene repopulation in a single control an- 
imal. Genomic DNA (5/~g) from spleen (S), thymus (T), bone marrow 
(BM), splenic B cells (B), and peritoneal macrophages  were analyzed as 
described in the Materials and Methods; dl, endogenous single-copy  con- 
trol. (/3) Average  repopulation with transgenically-marked  cells from a group 
of ten recipients. The columns filled with hatched shading represent the 
observed repopulation with B-type cells; the solid black columns repre- 
sent the percent repopulation  with A-type cells. Error bars delineate limits 
of the standard error of the calculated mean (SEM). 
Figure 3.  Effect  of LIF on hematopoietic repopulation. (A) Southern 
analysis of  transgene repopulation in a single  recipient, animal 24.6. DNA 
was analyzed as described in the legend to Fig. 2 and in the Materials 
and Methods; dl, single-copy  control. Abbreviations are as in the legend 
to Fig. 2. Genomic  DNA from these tissues was also studied  with an hADA 
cDNA probe to measure provirus representation. (B) B-type cells cultured 
without  added cytokines. (C) B-type cells cultured with  10 U/mL  LIF. 
(/9) B-type  cells with 1,000  U/mL LIF.  The figures  represent average  repopu- 
lation with transgenically-marked  cells from groups of ten recipients. The 
columns filled with hatched shading show the observed  repopulation with 
B-type cells; the solid black columns represent the percent repopulation 
with A-type cells. Error bars delineate limits of the standard error of the 
calculated mean (SEM). Abbreviations are as in the legend to Fig. 2. 
Culture  of B-type cells  with  10  U/ml LIF, followed by 
competitive repopulation with untreated cells of the A-type, 
resulted  in  an  average  79%  (:t:  6%)  reconstitution  with 
progeny of  LIF-treated stem cells in all (10/10) recipient animals 
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average of 11% (_+  2%), consistent with the A- and B-type 
controls cultured without added LIE Analysis of transgene 
representation in CFU-S derived from bone marrow of these 
recipients correlated with Southern blot analysis of primary 
hematopoietic tissues, with an average 88% (139/157  total 
colonies from 10 animals)  of spleen colonies derived from 
LIF-treated (B-type) stem cells. Ten percent (16/158) of spleen 
colonies were derived from A-type cells and 3% (4/157) of 
colonies were derived from endogenous stem cells that sur- 
vived irradiation (Fig.  4 B). 
At 1,000 U/ml LIF, a result similar to the 10 U/ml condi- 
tion was obtained in the competitive repopulation assay, with 
progeny of LIF-treated stem cells representing 71% (_+ 6%), 
on average, of hematopoietic cells present in the reconstituted 
recipients (Fig. 3/9). A-type cells represented an average of 
15  +  3% of differentiated progeny in these animals. Anal- 
ysis of repopulated CFU-S confirmed the finding in primary 
recipients,  with an average of 78% (102/131) of total spleen 
colonies derived from LIF-treated stem cells, 16% (21/131) 
from A-type cells, and 6% (8/131) from endogenous repopu- 
lation (Fig.  4 B). 
Retroviral Gene Transfer to Stem Cells.  Proviral sequences 
were not detectable by Southern blotting in primary hema- 
topoietic tissues of recipients transplanted with marrow cul- 
tured in the absence of LIF. Southern blotting and PCR anal- 
ysis of proviral representation in the B-type CFU-S from these 
animals, however, revealed that 79% (15 provirus positive of 
19 total) harbored the provirus. 
All (20/20) recipients of LIF-treated marrow had proviral 
integration that could be detected by Southern blotting in 
hematopoietic tissues following reconstitution. At 10 U/ml 
LIE two copies of provirus, on average, were detected per 
B-type cell (Table 1). Analysis of repopulated CFU-S from 
these animals revealed that, of the B-type colonies present, 
an average of 70% (98/139) were infected (Fig. 4 B). Provirus- 
positive CFU-S were recovered from all (10/10) 10 U/ml LIF 
primary animals, representing from 8% to 100% of B-type 
colonies per animal (Table 1). Proviral copy number detected 
in the bone marrow of each primary recipient was consistent 
with the percentage of provirus-positive CFU-S generated 
from that bone marrow. 
At 1,000 U/ml LIF, the average proviral copy number was 
0.7 per B-type cell (data not shown). Analysis of CFU-S from 
these animals  showed that of the B-type colonies present, 
69%  (75/102)  had  detectable provirns.  Provirus-positive 
CFU-S were recovered from 9/10 1,000 #/ml LIF animals, 
representing 25-100%  of B-type spleen  colonies per  an- 
imal (data not shown). Again, proviral copy number mea- 
sured in the bone marrows of primary recipients was consis- 
tent with the percentage of provirns-positive CFU-S generated 
from each marrow. 
Analysis of proviral junctions in repopulated CFU-S re- 
vealed oligodonal reconstitution in primary animals receiving 
LIF-treated marrow (Fig. 4 A). Production of CFU-S from 
a single infected stem cell predominated in most animals, how- 
ever, with additional stem cells either quiescent or contributing 
very low numbers of differentiated hematopoietic cells. 
Expression of Vector-Encoded Human Adenosine Deaminase. 
Expression of vector-encoded hADA was examined in hema- 
topoiesis tissues of recipient animals at the time of sacrifice 
(6 mo posttransplantation). Western blots of protein extracts 
were developed with a hADA-specific antibody, revealing in- 
creased levels of hADA protein in animals receiving LIF-treated 
marrow, compared to controls. To estimate the amount of 
human ADA expressed by vector transduced cells, immu- 
noblots were analyzed by quantitative video-imaging den- 
sitometry. Human ADA-specific bands on individual nitro- 
cellulose filters were corrected for variances in transfer  and 
development by comparison to a positive control (Molt4) on 
Table  1.  Recovery and Infection Efficiency of CFU-S Derived  from Primary Transplant Recipients 
Endogenous  Infection 
Animal  colonies  A-type colonies  B-type colonies  efficiency 
24.1  0/13  (0)  2/13 (15)  11/13  (85)  7/11  (64) 
24.2  0/12  (0)  2/12 (17)  10/12  (83)  8/10  (80) 
24.3  0/15  (0)  3/15 (20)  12/15  (80)  8/12  (67) 
24.4  0/19  (0)  2/19  (9)  17/19  (91)  16/17  (94) 
24.5  1/13  (5)  2/13 (15)  10/13  (80)  6/10  (60) 
24.11  3/17 (18)  1/17  (6)  13/17  (76)  9/13  (69) 
24.12  0/14  (0)  2/14 (14)  12/14  (86)  1/12  (8) 
24.13  0/21  (0)  0/21  (0)  21/21  (100)  10/21  (48) 
24.14  0/9  (0)  0/9  (0)  9/9  (100)  9/9  (100) 
24.15  0/24  (0)  0/24  (0)  24/24  (100)  24/24  (100) 
B-type marrow  was  exposed  to  10 U/ml  LIF during  72-h cocultivation with  the retroviral vector producing  cell line. 
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tivity in these transplant controls is unclear but may repre- 
sent relative depletion of the cells expressing the highest levels 
of the enzyme. Further comparison of hADA levels with en- 
dogenous mouse is also contained in Table 3. The estimated 
levels of hADA in the mice transplanted with the LIF-treated 
marrow ranged from 18 to 130% in the various tissues. The 
levels of hADA were substantially lower in the non-LIF treated 
retrovirally-infected marrow group ranging from 5 to 25% 
of the control. A further comparison was made between the 
mean levels of hADA expression in the LIF treated group 
vs. the no-LIF control group. The levels of hADA in the 10 
U/ml LIF group were 2.2-12-fold the no-LIF control. Like- 
wise the 1,000 U/ml LIF group demonstrated levels of hADA 
that ranged from 1.5 to 8.4-fold the no-LIF control. Quan- 
titative analysis of hADA levels revealed no absolute correla- 
tion between proviral copy number and expression, when 
measured either within individual animals or across  tissue 
groups. This suggests that integration position effects play 
an important role in the level of expression from the individual 
stem cell clones. 
Figure 4.  Analysis ofrepopulated  CFU-S. (A) Southern blot of unique 
proviral integrations  in B-type repopulated CFU-S.  Shown are colonies 
from  a single animal,  24.6;  analyzed as described in the Materials and 
Methods.  Bands from each of the transgene markers and the integrated 
provirus are indicated. (/3) Average  transgene representation  in clonal CFU-S 
derived from primary bone marrow  of each animal. Columns represent 
average number of colonies  with each type of transgenic marker (A - A-type; 
B - B-type; end - endogenous nontransgenic) divided by the total number 
of colonies. To control for statistical effects of differing numbers of colo- 
nies derived from separate animals, averages were calculated on a per an- 
imal basis, rather than as a percentage of total colonies. The shaded area 
in the B column represents the average percentage of CFU-S bearing the 
ADA vector provirus. 
each filter.  The hADA concentration was predicted from a 
standard curve based on purified recombinant human ADA 
and expressed as nM/min/mg. The level of hADA protein 
was variable between animals in each treatment group and 
within tissues  from single recipients (Table  2). 
We also compared the quantity of hADA protein to var- 
ious control groups. Endogenous ADA expression was mea- 
sured spectrophotometrically  both in normal non-transplanted 
mice and a group transplanted with flesh marrow not in- 
fected by the hADA retrovirus. The results of control ratios 
are depicted in Table 3. In the first transplant control group 
the level of endogenous ADA ranges from 1.2-fold to 2.5- 
fold the nontransplant group in all tissues except the thymus. 
Discussion 
Recovery of infected hematopoietic stem cells from cocul- 
ture with vector-producing fibroblasts has been a limiting 
factor in developing models for human gene therapy. We have 
observed that LIF directly or indirectly promoted survival 
of hematopoietic stem cells in vitro, and that stem cells re- 
covered from LIF-treated cultures exhibited a significant com- 
petitive advantage over untreated cells in repopulating the 
hematopoietic  system  of  irradiated  transplant  recipients. 
Moreover, the retroviral vector infection efficiency of LIF- 
treated stem cells was high, resulting in hematopoietic recon- 
stitution  of all recipients with progeny of at least one in- 
fected stem cell. Oligodonal hematopoiesis was observed in 
the transplanted animals, but a single infected clone predomi- 
nated in each animal. The observation of predominant clones 
in these animals precludes direct estimation of stem cell in- 
fection efficiency because of the skewing of relative activity 
between different stem cells. Since most of the CFU-S from 
individual primary recipients analyzed were derived from a 
few stem cell clones, the 70% infection efficiency of repopu- 
fated CFU-S only roughly corresponds to the absolute stem 
cell infection efficiency. Nearly complete hematopoietic recon- 
stitution with infected stem cells enabled expression of vector- 
encoded hADA at physiologically relevant levels in the im- 
portant  lymphoid compartments  for  at  least  6  mo  in  all 
recipient animals. 
The mechanism by which LIF stimulation improved stem 
cell survival is unknown, but could include a direct effect 
of LIF alone or in combination with other cytokines on stem 
cells, and/or an indirect effect on marrow accessory cells or 
the vector-producing fibroblasts.  Because the source of the 
LIF in these experiments was a Cos cell derived conditioned 
medium, a contribution of cytokine activity from the Cos 
cells cannot be excluded. In previous experiments (16) no effect 
of the Cos conditioned media alone was observed on primary 
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Animal  Growth factor  Spleen  Thymus  Bone marrow  B Cell  M~  Blood 
4.1  None  4.1  0.8  12.0  6.9  ND  0 
4.2  4.3  0.5  6,7  19.1  ND  0.2 
4.3  5.4  0.1  2.4  4.9  ND  0 
4.4  2.4  0  4.5  2.4  0.4  0 
4.5  2.1  0.9  2.5  13.8  2.6  0 
4.6  4.9  2.6  9.6  20.3  11.9  0,7 
4.7  ND  ND  ND  ND  ND  ND 
4.8  0  0  3.1  0  0  0 
Average  3.3  0.7  5.8  9.6  3.7  0.1 
24.1  10 U/ml LIF  22.1  10.9  45.8  25.1  7.7  2.2 
24.2  7.9  7.8  8.4  43.3  42.4  1,8 
24.3  ND  ND  5.1  29.2  10.7  0.4 
24.4  9.2  22.7  9.1  29.9  16.2  6.0 
24.5  12.2  5.8  13.4  31.3  1.8  0.5 
24.11  7.4  10.4  5.3  12.7  8.1  0.3 
24.12  9.5  6.1  9.1  11.9  8.3  0.1 
24.13  4.8  4.2  4.6  8.1  20.7  0.2 
24.14  6.7  4,8  17.9  14.3  8.3  0.1 
24.15  6.2  4.4  11.4  9.9  8.7  0.5 
Average  9.6  8.6  13.0  21.6  13.3  1.2 
hADA levels are reported in units of nanomoles  ADA activity/minute/milligram total protein. Protein extracts were prepared and hADA quantitated 
as described in the Materials and Methods. Indicated growth factors were added to cultures of B-type cells prior to competitive repopulation with 
untreated A-type cells. There was no significant difference in hADA protein levels between animals in the 10 U/mL and 1,000 U/ml groups. 
CFU-S survival or retroviral vector infection efficiency. Syn- 
ergistic interaction of LIF with cytokine(s) present at sub- 
threshold levels in the Cos media are a possibility.  We have 
Table 3.  Comparison of Relative ADA  Expression in 
Transplant Recipients 
Group  Spleen  Thymus  Marrow  B Cell  Blood 
Control*  1.3  0.03  1.7  1.2  2.5 
0  U/mL LIF*  0.18  0.05  0.11  0.25  0.11 
10 U/mL LIF  0.54  0.60  0.25  0.56  1.3 
Ratio  s  2.9  12.0  2.2  ~1.5  12.0 
" Control: Five mice were transplanted with fresh marrow not infected 
with the human ADA retrovirus. Endogenous ADA levels were deter- 
mined spectrophotometrically  and are expressed as the ratio of transplant 
control to normal nontransplant control. 
* Human ADA expression  in the different experimental  groups compared 
to the level of endogenous ADA expression in normal nontransplanted 
FVB mice. The results are expressed as the ratio of transplant group to 
normal adult control. ADA levels from infected transplant groups and 
controls are listed in Table 2. 
S Ratio of the mean  levels of hADA in the LIF treated transplant group 
vs. the no growth factor group. The ratios for cultured macrophages 
was 3.6. The mean values from each group are in Table 2. 
generated preliminary evidence (not shown) suggesting that 
FACS-sorted stem cells  (WGA +,  CD4-,  CDf-,  B220-, 
Mac-l-; "o200-fold CFU-S purification) are infected at high 
efficiency (80%)  during  coculture with  vector-producing 
fibroblasts in the presence of LIF, thus possibly removing the 
majority of marrow accessory cells from consideration as LIF 
targets in this system. It is possible that LIF-treatment in- 
duced secondary cytokine production by, or acted in combi- 
nation with factors normally secreted from the vector-pro- 
ducing fibroblasts present in our system. We were unable to 
detect the production of either IL-6 or IL-3 bioactivity by 
whole bone marrow or vector-producing fibroblasts in re- 
sponse to LIF stimulation (data not shown), suggesting that 
the induction of these factors did not produce the present 
results. Production of the recently identified stem cell factor 
(MGF) by fibroblasts  in vitro (22) was interesting in this re- 
gard, and we have begun investigating a possible interaction 
between LIF and MGF on the survival and proliferation of 
purified stem cells in vitro. 
Although LIF can improve the recovery of pluripotent stem 
cells and preCFU-S from liquid bone marrow culture, there 
is no evidence that LIF has a direct proliferative effect on these 
cell populations. Purified (WGA § , lin-, Rhodamine-123  d~ll) 
stem cells are not induced to proliferate in liquid culture by 
LIF treatment, and proliferative  index (by [3H]thymidine in- 
843  Fletcher  et al. corporation)  is not improved by addition  of LIF to other 
defined cytokines, including MGF (data not shown). We sug- 
gest, rather,  that the primary effect of LIF in our system is 
the delay or prevention of stem cell commitment to differen- 
tiation,  an effect similar  to the LIF action on ES cells. 
An unexpected finding from these studies was that the few 
stem cells recovered from untreated cultures also were infected 
at high efficiency, suggesting that there is no inherent block 
to retroviral infection of stem cells in the absence of added 
cytokine, a result in agreement with our hypothesis of LIF 
action. We speculate that this high infection efficiency results 
from the very high titer of ADA vector produced from the 
packaging cell and the apparent  requirement  for very high 
multiplicity of infection in the stem cell pool. In addition, 
intrinsic variability of the vector packaging cell lines in their 
interaction with the marrow cells may influence the apparent 
infection efficiency. When cocultivation of the marrow cells 
with the vector packaging fibroblasts is used these cells may 
behave as a stromal microenvironment. The documented loss 
of stem cells during coculture (23) is suggested to have been 
responsible  for  the  previously-observed low proviral  copy 
number in transplanted  recipients,  not low stem cell infec- 
tion  efficiency per  se.  The  growth  and  differentiation  of 
marrow cells in culture might also affect the apparent infec- 
tion efficiency. For example, efficient infection of precursors 
that differentiated to more mature cells would appear to be 
low in these bioassays if the differentiation process led to loss 
of donogenic or repopulating activity among those cells in- 
fected with the vector. We hypothesize that the apparent in- 
crease in infection efficiency of primary CFU-S after LIF stim- 
ulation (16) reflects,  at least in part, a loss of infected CFU-S 
from cultures  without  cytokine support. 
In conclusion,  these results suggest that  LIF directly or 
indirectly maintains the hematopoietic stem cell phenotype 
in shortterm culture, thereby facilitating  recovery of stem cells. 
Stem cells recovered from LIF-treated cultures are efficiently 
infected and can repopulate the hematopoietic system of all 
transplanted animals, leading to longterm expression of vector- 
encoded hADA at significant  levels. The ability, demonstrated 
here, to repopulate all bone marrow transplant recipients with 
efficiently-infected  stem  cells  significantly  advances  gene 
transfer methodology in the murine model. Future studies 
on the effect of LIF in human hematopoietic precursor cul- 
tures  should indicate whether  similar protocols will allow 
efficient transduction  of human  stem cells  for the purpose 
of gene therapy. 
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